Takeda Korea said it appointed Park Kwang-kyu, also known as Kenny Park, as its new General Manager.

With over two decades of experience in the pharmaceutical industry, Park is recognized as an expert with strong leadership in specialty care and oncology, particularly in hematologic malignancies and immunotherapy.

Before joining Takeda Korea, Park worked in various global pharmaceutical companies, including BMS Korea, AstraZeneca Korea, and MSD Korea, where he led efforts in new drug introduction, organizational innovation, and stakeholder collaboration.

Most recently, he served as the Senior Director of Gilead Sciences Korea’s Liver Disease Business Unit.

Park holds a degree in pharmacy from Kyung Hee University and earned his MBA from Seoul National University’s Graduate School of Business.

“Takeda Korea has consistently pursued patient-centered innovation amid a rapidly evolving healthcare landscape,” said Park. “Moving forward, we will accelerate the introduction of innovative therapies and seek diverse solutions to ensure that both healthcare professionals and patients have access to optimal treatment opportunities.”

He further emphasized his commitment to strengthening collaboration with Korean biotech and pharmaceutical companies to improve the treatment environment and contribute to the sustainable development of Korea’s pharmaceutical industry.

Mahender Nayak, Senior Vice President of Growth and Emerging Markets at Takeda Pharmaceuticals expressed his confidence in Park’s leadership.

“We are thrilled to welcome Park to Takeda, especially as we advance six innovative late-stage pipeline assets,” Nayak said. “His extensive business experience and strategic leadership will be instrumental in ensuring Takeda Korea’s continued success.”